Non-traditional Antibacterial Therapeutic Options and Challenges

Cell Host and Microbe

Volumn 26, Issue 1, 2019, Pages 61-72

  Theuretzbacher, Ursula ^a   Piddock, Laura J V ^b  

^a Centre for Anti Infective Agents   (Austria)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

anti virulence; antisense RNA; immunotherapy; microbiome; nanoparticles; non traditional antimicrobials; phage; quorum sensing

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; COMPLEMENTARY RNA; NANOPARTICLE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MICROBIOME; BACTERIAL VIRULENCE; BACTERIOPHAGE; BACTERIUM ADHERENCE; BIOFILM; DOWN REGULATION; DRUG TARGETING; HOST CELL; HUMAN; IMMUNE EVASION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SECRETION (PROCESS); BACTERIAL INFECTION; BIOLOGICAL THERAPY; DRUG THERAPY; PROCEDURES;

BACTERIAL INFECTIONS; BIOLOGICAL THERAPY; DRUG THERAPY; HUMANS;

EID: 85068125859     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2019.06.004     Document Type: Review

References (108)

1. Aiello, D., Williams, J.D., Majgier-Baranowska, H., Patel, I., Peet, N.P., Huang, J., Lory, S., Bowlin, T.L., Moir, D.T., Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54 (2010), 1988–1999.
2. Allen, R.C., Popat, R., Diggle, S.P., Brown, S.P., Targeting virulence: can we make evolution-proof drugs?. Nat. Rev. Microbiol. 12 (2014), 300–308.
3. Anantharajah, A., Mingeot-Leclercq, M.P., Van Bambeke, F., Targeting the Type Three secretion system in Pseudomonas aeruginosa. Trends Pharmacol. Sci. 37 (2016), 734–749.
4. Anonye, B.O., Commentary: bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Front. Cell. Infect. Microbiol., 8, 2018, 104.
5. Azeredo da Silveira, S., Perez, A., Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials. Expert Rev. Anti Infect. Ther. 15 (2017), 973–975.
6. Baker, S.J., Payne, D.J., Rappuoli, R., De Gregorio, E., Technologies to address antimicrobial resistance. Proc. Natl. Acad. Sci. USA 115 (2018), 12887–12895.
7. Bakken, J.S., Borody, T., Brandt, L.J., Brill, J.V., Demarco, D.C., Franzos, M.A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L.P., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9 (2011), 1044–1049.
8. Baptista, P.V., McCusker, M.P., Carvalho, A., Ferreira, D.A., Mohan, N.M., Martins, M., Fernandes, A.R., Nano-strategies to fight multidrug resistant bacteria-"a battle of the titans". Front. Microbiol., 9, 2018, 1441.
9. Barbu, E.M., Cady, K.C., Hubby, B., Phage therapy in the era of synthetic biology. Cold Spring Harb. Perspect. Biol., 8, 2016 a023879.
10. Bäumler, A.J., Sperandio, V., Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535 (2016), 85–93.
11. Bikard, D., Euler, C.W., Jiang, W., Nussenzweig, P.M., Goldberg, G.W., Duportet, X., Fischetti, V.A., Marraffini, L.A., Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat. Biotechnol. 32 (2014), 1146–1150.
12. Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., Marraffini, L.A., Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 41 (2013), 7429–7437.
13. Boers, S.A., Jansen, R., Hays, J.P., Suddenly everyone is a microbiota specialist. Clin. Microbiol. Infect. 22 (2016), 581–582.
14. Borody, T.J., Campbell, J., Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol. Clin. North Am. 41 (2012), 781–803.
15. Briers, Y., Lavigne, R., Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol. 10 (2015), 377–390.
16. Buckner, M.M.C., Ciusa, M.L., Piddock, L.J.V., Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing. FEMS Microbiol. Rev. 42 (2018), 781–804.
17. Bull, J.J., Gill, J.J., The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front. Microbiol., 5, 2014, 618.
18. Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 66 (2017), 569–580.
19. Cascioferro, S., Raffa, D., Maggio, B., Raimondi, M.V., Schillaci, D., Daidone, G., Sortase A inhibitors: recent advances and future perspectives. J. Med. Chem. 58 (2015), 9108–9123.
20. Cathcart, G.R.A., Quinn, D., Greer, B., Harriott, P., Lynas, J.F., Gilmore, B.F., Walker, B., Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection. Antimicrob. Agents Chemother. 55 (2011), 2670–2678.
21. Chang, R.Y.K., Wallin, M., Lin, Y., Leung, S.S.Y., Wang, H., Morales, S., Chan, H.-K., Phage therapy for respiratory infections. Adv. Drug Deliv. Rev. 133 (2018), 76–86.
22. Chiang, C.Y., Uzoma, I., Moore, R.T., Gilbert, M., Duplantier, A.J., Panchal, R.G., Mitigating the impact of antibacterial drug resistance through host-directed therapies: current progress, outlook, and challenges. mBio, 9, 2018 e01932–01917.
23. Cooper, C.J., Khan Mirzaei, M., Nilsson, A.S., Adapting drug approval pathways for bacteriophage-based therapeutics. Front. Microbiol., 7, 2016, 1209.
24. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A., Foster, S., Gilmore, B.F., Hancock, R.E.W., Harper, D., et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect. Dis. 16 (2016), 239–251.
25. Dąbrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., Kaźmierczak, Z., Letarov, A., Górski, A., Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88 (2014), 12551–12557.
26. Das, S., Angsantikul, P., Le, C., Bao, D., Miyamoto, Y., Gao, W., Zhang, L., Eckmann, L., Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera. PLOS Negl. Trop. Dis., 12, 2018, e0006266.
27. Defoirdt, T., Quorum-sensing systems as targets for antivirulence therapy. Trends Microbiol. 26 (2018), 313–328.
28. Deng, W., Marshall, N.C., Rowland, J.L., McCoy, J.M., Worrall, L.J., Santos, A.S., Strynadka, N.C.J., Finlay, B.B., Assembly, structure, function and regulation of type III secretion systems. Nat. Rev. Microbiol., 15, 2017, 323.
29. Dickey, S.W., Cheung, G.Y.C., Otto, M., Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat. Rev. Drug Discov, 16, 2017, 457.
30. DiGiandomenico, A., Keller, A.E., Gao, C., Rainey, G.J., Warrener, P., Camara, M.M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci. Transl. Med., 6, 2014, 262ra155.
31. Fasciano, A.C., Shaban, L., Mecsas, J., Promises and challenges of the Type Three secretion system injectisome as an antivirulence target. EcoSal Plus, 8, 2019.
32. Fauconnier, A., Regulating phage therapy: the biological master file concept could help to overcome regulatory challenge of personalized medicines. EMBO Rep. 18 (2017), 198–200.
33. Fernandes, S., São-José, C., Enzymes and mechanisms employed by tailed bacteriophages to breach the bacterial cell barriers. Viruses, 10, 2018, 396.
34. Fischetti, V.A., Development of phage lysins as novel therapeutics: a historical perspective. Viruses, 10, 2018, 310.
35. Food and Drug Administration (FDA). (2016). USA. In Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Draft Gudance for industry. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
36. Food and Drug Administration (FDA). (2019). USA. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse.
37. Gao, P., Ho, P.L., Yan, B., Sze, K.H., Davies, J., Kao, R.Y.T., Suppression of Staphylococcus aureus virulence by a small-molecule compound. Proc. Natl. Acad. Sci. USA 115 (2018), 8003–8008.
38. Garland, M., Loscher, S., Bogyo, M., Chemical strategies to target bacterial virulence. Chem. Rev. 117 (2017), 4422–4461.
39. Good, L., Stach, J.E., Synthetic RNA silencing in bacteria - antimicrobial discovery and resistance breaking. Front. Microbiol., 2, 2011, 185.
40. Gu, L., Zhou, S., Zhu, L., Liang, C., Chen, X., Small-molecule inhibitors of the Type III secretion system. Molecules, 20, 2015, 17659.
41. Gutiérrez, D., Fernández, L., Rodríguez, A., García, P., Are phage lytic proteins the secret weapon to kill Staphylococcus aureus?. mBio, 9, 2018 e01923–01917.
42. Haddad Kashani, H., Schmelcher, M., Sabzalipoor, H., Seyed Hosseini, E., Moniri, R., Recombinant endolysins as Potential Therapeutics against antibiotic-resistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin. Microbiol. Rev., 31, 2018 e00071–00017.
43. Haque, S., Ahmad, F., Dar, S.A., Jawed, A., Mandal, R.K., Wahid, M., Lohani, M., Khan, S., Singh, V., Akhter, N., Developments in strategies for Quorum Sensing virulence factor inhibition to combat bacterial drug resistance. Microb. Pathol. gen 121 (2018), 293–302.
44. Harper, D.R., Criteria for selecting suitable infectious diseases for phage therapy. Viruses, 10, 2018, 177.
45. Hatoum-Aslan, A., Phage genetic engineering using CRISPR-Cas systems. Viruses, 10, 2018, 335.
46. Heras, B., Scanlon, M.J., Martin, J.L., Targeting virulence not viability in the search for future antibacterials. Br. J. Clin. Pharmacol. 79 (2015), 208–215.
47. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapała, J., Drab, M., Jończyk-Matysiak, E., Lecion, D., Kaźmierczak, Z., Beta, W., Majewska, J., Harhala, M., et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep., 5, 2015, 14802.
48. Hong, X., Qin, J., Li, T., Dai, Y., Wang, Y., Liu, Q., He, L., Lu, H., Gao, Q., Lin, Y., et al. Staphylococcal protein A promotes colonization and immune evasion of the epidemic healthcare-associated MRSA ST239. Front. Microbiol., 7, 2016, 951.
49. Huttner, B.D., de Lastours, V., Wassenberg, M., Maharshak, N., Mauris, A., Galperine, T., Zanichelli, V., Kapel, N., Bellanger, A., Olearo, F., et al. A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clin. Microbiol. Infect., 2019 1930030-8, S1198–S1743X.
50. Inchley, C.J., The actvity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin. Exp. Immunol. 5 (1969), 173–187.
51. Iqbal, U., Anwar, H., Karim, M.A., Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection. Eur. J. Gastroenterol. Hepatol. 30 (2018), 730–734.
52. Jun, S.Y., Jang, I.J., Yoon, S., Jang, K., Yu, K.-S., Cho, J.Y., Seong, M.-W., Jung, G.M., Yoon, S.J., Kang, S.H., Pharmacokinetics and tolerance of the phage endolysin-based candidate drug SAL200 after a Single Intravenous Administration among healthy volunteers. Antimicrob. Agents Chemother., 61, 2017 e02629–02616.
53. Kalas, V., Hibbing, M.E., Maddirala, A.R., Chugani, R., Pinkner, J.S., Mydock-McGrane, L.K., Conover, M.S., Janetka, J.W., Hultgren, S.J., Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. Proceedings of the national. Proc. Natl. Acad. Sci. USA 115 (2018), E2819–E2828.
54. Khanna, S., Pardi, D.S., Kelly, C.R., Kraft, C.S., Dhere, T., Henn, M.R., Lombardo, M.J., Vulic, M., Ohsumi, T., Winkler, J., et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214 (2016), 173–181.
55. Kim, N.H., Park, W.B., Cho, J.E., Choi, Y.J., Choi, S.J., Jun, S.Y., Kang, C.K., Song, K.H., Choe, P.G., Bang, J.H., et al. Effects of phage endolysin SAL200 combined with antibiotics on Staphylococcus aureus infection. Antimicrob. Agents Chemother., 62, 2018 e00731–00718.
56. Koropatkin, N.M., Cameron, E.A., Martens, E.C., How glycan metabolism shapes the human gut microbiota. Nat. Rev. Microbiol. 10 (2012), 323–335.
57. Kortright, K.E., Chan, B.K., Koff, J.L., Turner, P.E., Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25 (2019), 219–232.
58. Krom, R.J., Bhargava, P., Lobritz, M.A., Collins, J.J., Engineered phagemids for nonlytic, targeted antibacterial therapies. Nano Lett. 15 (2015), 4808–4813.
59. Krut, O., Bekeredjian-Ding, I., Contribution of the immune response to phage therapy. J. Immunol. 200 (2018), 3037–3044.
60. Kwon, E.J., Skalak, M., Bertucci, A., Braun, G., Ricci, F., Ruoslahti, E., Sailor, M.J., Bhatia, S.N., Porous silicon nanoparticle delivery of tandem peptide anti-infectives for the treatment of Pseudomonas aeruginosa Lung infections. Adv. Mater., 29, 2017, 1701527.
61. Lukacik, P., Barnard, T.J., Keller, P.W., Chaturvedi, K.S., Seddiki, N., Fairman, J.W., Noinaj, N., Kirby, T.L., Henderson, J.P., Steven, A.C., et al. Structural engineering of a phage lysin that targets gram-negative pathogens. Proc. Natl. Acad. Sci. USA 109 (2012), 9857–9862.
62. Maddirala, A.R., Klein, R., Pinkner, J.S., Kalas, V., Hultgren, S.J., Janetka, J.W., Biphenyl Gal and GalNAc FmlH lectin antagonists of uropathogenic E. coli (UPEC): optimization through iterative rational drug design. J. Med. Chem. 62 (2019), 467–479.
63. Mamusa, M., Sitia, L., Barbero, F., Ruyra, A., Calvo, T.D., Montis, C., Gonzalez-Paredes, A., Wheeler, G.N., Morris, C.J., McArthur, M., et al. Cationic liposomal vectors incorporating a bolaamphiphile for oligonucleotide antimicrobials. Biochim. Biophys. Acta rev. Biomembr. 1859 (2017), 1767–1777.
64. Maura, D., Ballok, A.E., Rahme, L.G., Considerations and caveats in anti-virulence drug development. Curr. Opin. Microbiol. 33 (2016), 41–46.
65. Maura, D., Drees, S.L., Bandyopadhaya, A., Kitao, T., Negri, M., Starkey, M., Lesic, B., Milot, S., Déziel, E., Zahler, R., et al. Polypharmacology approaches against the Pseudomonas aeruginosa MvfR regulon and their application in blocking virulence and antibiotic tolerance. ACS Chem. Biol. 12 (2017), 1435–1443.
66. McConville, T.H., Sullivan, S.B., Gomez-Simmonds, A., Whittier, S., Uhlemann, A.C., Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PloS One, 12, 2017, e0186195.
67. Merabishvili, M., Monserez, R., van Belleghem, J., Rose, T., Jennes, S., De Vos, D., Verbeken, G., Vaneechoutte, M., Pirnay, J.P., Stability of bacteriophages in burn wound care products. PloS One, 12, 2017, e0182121.
68. Mullish, B.H., Quraishi, M.N., Segal, J.P., McCune, V.L., Baxter, M., Marsden, G.L., Moore, D.J., Colville, A., Bhala, N., Iqbal, T.H., et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 67 (2018), 1920–1941.
69. NIH HMP Working Group Peterson, J., Garges, S., Giovanni, M., McInnes, P., Wang, L., Schloss, J.A., Bonazzi, V., McEwen, J.E., Wetterstrand, K.A., et al. The NIH Human Microbiome Project. Genome Res. 19 (2009), 2317–2323.
70. Oechslin, F., Piccardi, P., Mancini, S., Gabard, J., Moreillon, P., Entenza, J.M., Resch, G., Que, Y.-A., Synergistic interaction Between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J. Infect. Dis. 215 (2017), 703–712.
71. Oliveira, H., são-José, C., Azeredo, J., Phage-derived peptidoglycan degrading enzymes: challenges and future prospects for in vivo therapy. Viruses, 10, 2018, 292.
72. Ooijevaar, R.E., van Beurden, Y.H., Terveer, E.M., Goorhuis, A., Bauer, M.P., Keller, J.J., Mulder, C.J.J., Kuijper, E.J., Update of treatment algorithms for Clostridium difficile infection. Clin. Microbiol. Infect. 24 (2018), 452–462.
73. Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D.S., Ramesh, M.S., PUNCH CD Investigators. Safety and durability of RBX2660 (microbiota suspension) for recurrent clostridium difficile infection: results of the PUNCH CD study. Clin. Microbiol. Infect. 62 (2016), 596–602.
74. Pastagia, M., Schuch, R., Fischetti, V.A., Huang, D.B., Lysins: the arrival of pathogen-directed anti-infectives. J. Med. Microbiol. 62 (2013), 1506–1516.
75. Paule, A., Frezza, D., Edeas, M., Microbiota and phage therapy: future challenges in medicine. Med. Sci. (Basel), 6, 2018, E86.
76. PHAGOBURN. Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (phase I–II clinical trial). https://cordis.europa.eu/project/rcn/108695/reporting/en, 2018.
77. Pires, D.P., Cleto, S., Sillankorva, S., Azeredo, J., Lu, T.K., Genetically engineered phages: a review of advances over the last decade. Microbiol. Mol. Biol. Rev. 80 (2016), 523–543.
78. Pirnay, J.-P., Verbeken, G., Ceyssens, P.-J., Huys, I., De Vos, D., Ameloot, C., Fauconnier, A., The magistral phage. Viruses, 10, 2018, 64.
79. Pirofski, L.-a., Casadevall, A., Immunomodulators as an antimicrobial tool. Curr. Opin. Microbiol. 9 (2006), 489–495.
80. Relman, D.A., Lipsitch, M., Microbiome as a tool and a target in the effort to address antimicrobial resistance. Proc. Natl. Acad. Sci. USA 115 (2018), 12902–12910.
81. Rémy, B., Mion, S., Plener, L., Elias, M., Chabrière, E., Daudé, D., Interference in bacterial quorum sensing: a biopharmaceutical perspective. Front. Pharmacol, 9, 2018, 203.
82. Rezzoagli, C., Wilson, D., Weigert, M., Wyder, S., Kümmerli, R., Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in Pseudomonas aeruginosa. Evol. Med. Public Health 1 (2018), 246–259.
83. Rohde, C., Wittmann, J., Kutter, E., Bacteriophages: a therapy concept against multi-drug-resistant bacteria. Surg. Infect. 19 (2018), 737–744.
84. Rose, T., Verbeken, G., Vos, D.D., Merabishvili, M., Vaneechoutte, M., Lavigne, R., Jennes, S., Zizi, M., Pirnay, J.P., Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4 (2014), 66–73.
85. Salam, A.M., Quave, C.L., Targeting virulence in Staphylococcus aureus by chemical inhibition of the accessory gene regulator system in vivo. mSphere, 3, 2018 e00500–00517.
86. São-José, C., Engineering of phage-derived lytic enzymes: improving their potential as antimicrobials. Antibiotics (Basel, Switzerland), 7, 2018, 29.
87. Schirmeier, E., Zimmermann, P., Hofmann, V., Biebl, M., Gerstmans, H., Maervoet, V.E.T., Briers, Y., Inhibitory and bactericidal effect of Artilysin® Art-175 against colistin-resistant mcr-1-positive Escherichia coli isolates. Int. J. Antimicrob. Agents 51 (2018), 528–529.
88. Schuch, R., Lee, H.M., Schneider, B.C., Sauve, K.L., Law, C., Khan, B.K., Rotolo, J.A., Horiuchi, Y., Couto, D.E., Raz, A., et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J. Infect. Dis 209 (2014), 1469–1478.
89. Self, W.H., Wunderink, R.G., DiNubile, M.J., Stossel, T.P., Levinson, S.L., Williams, D.J., Anderson, E.J., Bramley, A.M., Jain, S., Edwards, K.M., et al. Low admission plasma gelsolin concentrations identify community-acquired pneumonia patients at high risk for severe outcomes. Clin. Infect. Dis., 2018, 10.1093/cid/ciy1049.
90. Servick, K., DRUG DEVELOPMENT. Beleaguered phage therapy trial presses on. Science, 352, 2016, 1506.
91. Smillie, C.S., Sauk, J., Gevers, D., Friedman, J., Sung, J., Youngster, I., Hohmann, E.L., Staley, C., Khoruts, A., Sadowsky, M.J., et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23 (2018), 229–240.e5.
92. Spaulding, C.N., Hultgren, S.J., Adhesive pili in UTI pathogenesis and drug development. Pathogens, 5, 2016, E30.
93. Spaulding, C.N., Klein, R.D., Schreiber, H.L., Janetka, J.W., Hultgren, S.J., Precision antimicrobial therapeutics: the path of least resistance?. NPJ Biofilms Microbiomes, 4, 2018.
94. Sully, E.K., Geller, B.L., Antisense antimicrobial therapeutics. Curr. Opin. Microbiol. 33 (2016), 47–55.
95. Theuretzbacher, U., Savic, M., Årdal, C., Outterson, K., Market watch: innovation in the preclinical antibiotic pipeline. Nat. Rev. Drug Discov. 16 (2017), 744–745.
96. Timmis, K., Timmis, J.K., Brüssow, H., Fernández, L.Á., Synthetic consortia of nanobody-coupled and formatted bacteria for prophylaxis and therapy interventions targeting microbiome dysbiosis-associated diseases and co-morbidities. Microb. Biotechnol. 12 (2019), 58–65.
97. Totsika, M., Benefits and challenges of antivirulence antimicrobials at the dawn of the post-antibiotic era. Curr. Medicin. Chem. 6 (2016), 30–37.
98. Varshney, A.K., Kuzmicheva, G.A., Lin, J., Sunley, K.M., Bowling, R.A. Jr., Kwan, T.Y., Mays, H.R., Rambhadran, A., Zhang, Y., Martin, R.L., et al. A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PloS One, 13, 2018, e0190537.
99. Vila, J., Microbiota transplantation and/or CRISPR/Cas in the battle against antimicrobial resistance. Clin. Microbiol. Infect. 24 (2018), 684–686.
100. Wang, L., Hu, C., Shao, L., The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int. J. Nanomed Volume (2017), 1227–1249.
101. Wang-Lin, S.X., Balthasar, J.P., Pharmacokinetic and pharmacodynamic considerations for the use of monoclonal antibodies in the treatment of bacterial infections. Antibodies, 7, 2018, 5.
102. Williams, P., Strategies for inhibiting quorum sensing. Emerg. Top. Life Sci. 1 (2017), 23–30.
103. Wilson, B.C., Vatanen, T., Cutfield, W.S., O'Sullivan, J.M., The super-donor phenomenon in fecal microbiota transplantation. Front. Cell. Infect. Microbiol., 9, 2019, 2.
104. Wright, A., Hawkins, C.H., Änggård, E.E., Harper, D.R., A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34 (2009), 349–357.
105. Yosef, I., Manor, M., Kiro, R., Qimron, U., Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA 112 (2015), 7267–7272.
106. Young, V.B., Therapeutic manipulation of the microbiota: past, present, and considerations for the future. Clin. Microbiol. Infect. 22 (2016), 905–909.
107. Yu, X.-Q., Robbie, G.J., Wu, Y., Esser, M.T., Jensen, K., Schwartz, H.I., Bellamy, T., Hernandez-Illas, M., Jafri, H.S., Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob. Agents Chemother., 61, 2017 e01020–01016.
108. Zuo, T., Wong, S.H., Lam, K., Lui, R., Cheung, K., Tang, W., Ching, J.Y.L., Chan, P.K.S., Chan, M.C.W., Wu, J.C.Y., et al. Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome. Gut 67 (2018), 634–643.